Registered title, quoted from ClinicalTrials.gov
Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Tianjin Medical University Cancer Institute & Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT05686434, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Primary non-squamous NSCLC confirmed histologically by the central laboratory;
Inclusion criterion 3
As confirmed by the central laboratory, the tumor contains one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), alone or in conjunction with other EGFR mutations, including T790M;
Inclusion criterion 6
Central laboratory pathology confirmed solid and/or micropapillary component ≥10%, or STAS;
Inclusion criterion 8
At least 2 weeks prior to initiation of the study drug, female subjects should be using highly effective contraceptive methods, pregnancy tests must be negative, and there must be no ongoing breastfeeding prior to initiation of the drug, or else one of the following criteria must be met at the time of screening to demonstrate the possibility of non-fertility:
Inclusion criterion 12
Postmenopausal was defined as over 50 years of age and amenorrhea for at least 12 months after cessation of all exogenous hormone therapy.
Inclusion criterion 13
Women under 50 should be considered to have stopped menstruating if they have stopped menstruating for 12 months or more after stopping exogenous hormone therapy and their LH and FSH levels are within the agency's postmenopausal range.
Inclusion criterion 14
History of other malignancies, other than non-melanoma skin cancer, carcinoma in situ or other solid tumors that have been effectively treated, and the treating physician has determined that there is no evidence of disease recurrence for 5 years after treatment;
Exclusion criterion 3
The patient is pregnant or nursing;
Exclusion criterion 14
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05686434, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- The subject will voluntarily sign the informed consent in person, and provide the informed consent before any specific study procedures;
- Male and female, ≥18 years old;
- Primary non-squamous NSCLC confirmed histologically by the central laboratory;
- Brain imaging examinations should be performed before surgery or enrollment;
- The patient was clinically confirmed as stage I by imaging, and was staged according to the eighth edition of TNM lung cancer;
- As confirmed by the central laboratory, the tumor contains one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), alone or in conjunction with other EGFR mutations, including T790M;
- The primary NSCLC must be completely resected by surgery, and all lesions must be removed at the end of the surgery.All surgical margins must be negative. Lobectomy can be done with open surgery or thoracoscopic (VATS);
- Central laboratory pathology confirmed solid and/or micropapillary component ≥10%, or STAS;
- The interval from operation to adjuvant Osimertinib treatment is no more than 10 weeks;
- WHO physical status score is 0\~1;
- Paraffin-embedded sections (10-15 sheets), or wax blocks or fresh frozen tissue for surgical resection of the lesion should be provided;
- At least 2 weeks prior to initiation of the study drug, female subjects should be using highly effective contraceptive methods, pregnancy tests must be negative, and there must be no ongoing breastfeeding prior to initiation of the drug, or else one of the following criteria must be met at the time of screening to demonstrate the possibility of non-fertility:
- Postmenopausal was defined as over 50 years of age and amenorrhea for at least 12 months after cessation of all exogenous hormone therapy.
- Women under 50 should be considered to have stopped menstruating if they have stopped menstruating for 12 months or more after stopping exogenous hormone therapy and their LH and FSH levels are within the agency's postmenopausal range.
- Irreversible surgical sterilization recorded by hysterectomy, bilateral oophorectomy or bilateral salpingectomy, but not tubal ligation;Male subjects must be willing to use barrier contraception.
Exclusion Criteria:
- Exposure to other antitumor therapies before enrollment;
- Patients who only received segmental resection and wedge resection;
- History of other malignancies, other than non-melanoma skin cancer, carcinoma in situ or other solid tumors that have been effectively treated, and the treating physician has determined that there is no evidence of disease recurrence for 5 years after treatment;
- Evidence of any severe or uncontrolled systemic disease, including uncontrolled hypertension and active bleeding, any condition that the investigator considers to be detrimental to patient participation in the study or to adherence to the protocol, or active infections including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV). Omission requirement for screening chronic diseases;
- Any of the following cardiac criteria:
- QTc values obtained using screening clinic ECG machines mean resting corrected QT interval (QTc) > 470 milliseconds from 3 electrocardiogram (ECG) tests,
- Any abnormalities in rhythm, conduction, or morphology of a clinically significant resting ECG, such as left bundle branch block, third degree heart block, and second degree heart block.
- Any factors that increase the risk of prolonged QTc or arrhythmia events, such as heart failure, hypokalemia, congenital long QT syndrome, sudden unexplained death under 40 years of age in a first-degree relative or any concomitant medication known to prolong the QT interval.
- Any evidence of prior history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia requiring steroid treatment, or active interstitial lung disease;
- Lack of adequate bone marrow reserve or organ function (demonstrated by any of the following laboratory values: absolute neutrophil count <1.5×10⁹/L;Platelet count <100×10⁹/L;Hemoglobin <90 g/L;Alanine aminotransferase > 2.5 ULN; Aspartate aminotransferase >2.5 times ULN;Total bilirubin > 1.5 ULN;Serum creatinine >1.5 ULN with creatinine clearance <50 mL/min [as measured or calculated by Cockcroft and Gault formulas] - creatinine clearance only needs to be confirmed when creatinine >1.5 ULN);
- History of hypersensitivity to active or inactive excipients of Osimertinib or drugs with similar chemical structures or classes to ocitinib;
- Uncontrolled nausea and vomiting, chronic gastrointestinal illness, inability to swallow formulated drugs, or prior major bowel resection that prevents adequate absorption of Osimertinib;
- Any evidence of corneal injury confirmed by ophthalmic examination through slit lamp evaluation;
- The patient is pregnant or nursing;
- History of allergy to ocitinib active or inactive excipients or drugs similar in chemical structure or class to Osimertinib;
- If the patient is unlikely to comply with study procedures, restrictions, and requirements, the investigator judges that the patient should not participate in the study.
Quoted from ClinicalTrials.gov, NCT05686434, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT05686434, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.